- - Histologically confirmed MCC metastases in regional lymph node(s)
- Confirmation of the MCC diagnosis in the regional lymph node(s) is mandatory for
- - (NOTE: In-transit metastases without regional nodal involvement could be allowed,
but only after written approval of the medical monitor)
- Must have completed definitive treatment for primary MCC and regional lymphatic
metastases that included surgical removal (with/without adjuvant radiation therapy) or
primary radiation therapy as determined by the treating investigator.
- - Estimated life expectancy greater than 3 years.
- - Must start the study treatment no more than 120 days from the start date of definitive
therapy (the date of surgical removal of nodal metastases or the date of initiation of
definitive radiation therapy, as applicable)
- Eastern Co-Operative Group (Eastern Cooperative Oncology Group [ECOG]) performance
score of 0 or 1.
- - Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L.
- - Platelet count ≥ 100 x 10^9/L.
- - Hemoglobin ≥ 9 g/dL (may have been transfused)
- Total bilirubin level ≤ 1.5 x the upper limit of normal (ULN) range.
- - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤ 2.5 x ULN.
- - Estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula or
by 24-hour urine collection for creatinine clearance or according to local
- - Women of childbearing potential must have a negative serum or urine pregnancy test at
- - Both male and female subjects must be willing to use highly effective contraception
(that is, methods with a failure rate of less than 1% per year) throughout the study
and for at least 30 days after last avelumab treatment administration if the risk of
* (NOTE: The effects of the study treatment on the developing human fetus are unknown;
thus, women of childbearing potential and men must agree to use highly effective
contraception, as stipulated in national or local guidelines. Should a woman become
pregnant or suspect she is pregnant while she or her partner is participating in this
study, the treating physician should be informed immediately.)
- - Must have an ability to understand and the willingness to sign a written informed
- - Must consent to allow the acquisition of existing formalin-fixed paraffin-embedded
(FFPE) tumor tissue, either a block or unstained slides, for performance of
- - Clinical or radiologic suspicion of residual MCC at the time of enrollment.
- - Suspicion or known history of distant metastatic MCC, which is not classifiable as
local recurrence or regional metastasis.
- - Any prior systemic therapy (e.g. adjuvant, neo-adjuvant or concurrent use of
chemotherapy, immunotherapy or an investigational agent) for MCC at any time.
- - Any prior intra-lesional MCC therapy within 180 days from day 1 of study treatment.
- - Residual toxicity from prior therapy grade > 1 (National Cancer Institute [NCI]-Common
Terminology Criteria for Adverse Events [NCI-CTCAE v 5.0]) that could interfere with
study endpoints or put patient safety at risk.
- - Previous malignant disease (other than Merkel cell carcinoma) diagnosed within 3 years
from day 1 of study treatment that could interfere with study endpoints or put patient
safety at risk.
* (NOTE: Exception will be made for adequately treated basal or squamous cell
carcinoma of the skin or carcinoma in situ [skin, bladder, cervical, colorectal,
breast] or low grade prostatic intraepithelial neoplasia or Grade 1 prostate cancer;
any other neoplasm, which is adjudged by the treating investigator to have a low risk
of recurrence during the study, could be enrolled only after written approval from the
- - Use of any systemic immunosuppressive treatments including corticosteroids,
cyclosporine, mycophenolate mofetil et cetera, ongoing or within the last 3 months
prior to day 1 of treatment.
* (NOTE: Patients on physiologic dose of corticosteroids [≤ 10 mg/day of prednisone or
equivalent] for long-term hormone-replacement therapy or those requiring short,
intermittent courses of corticosteroids for hypersensitivity prophylaxis [such as for
iodinated computed tomography (CT) contrast prophylaxis] or those using intranasal,
inhaled, topical steroids, or local steroid injection [e.g., intra-articular
injection] can be allowed)
- - Immunosuppressed status due to known human immunodeficiency virus (HIV) infection,
severe uncontrolled diabetes, concurrent hematological malignancy, or other
- - Uncontrolled intercurrent illness including, but not limited to, active serious
infection, active hepatitis B or hepatitis C infection, uncontrolled seizure disorder,
substance abuse disorder, or psychiatric illness/social situations that would limit
compliance with study requirements or would put the patient at increased risk of
complications during the study period.
- - Clinically significant (i.e., active) cardiovascular disease: cerebral vascular
accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months
prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart
Association Classification Class II), or serious cardiac arrhythmia requiring
- - Active or history of any serious autoimmune disease, prior organ transplantation,
including allogeneic stem-cell transplantation or immune-deficiencies that required
treatment with systemic immunosuppressive drugs and could flare-up during study
* (NOTE: Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid
diseases not requiring immunosuppressive treatment are eligible)
- - Other severe acute or chronic medical conditions including immune-mediated colitis,
inflammatory bowel disease, pneumonitis, pulmonary fibrosis or psychiatric conditions
including recent (within the past year) or active suicidal ideation or behavior; or
laboratory abnormalities that may increase the risk associated with study
participation or study treatment administration or may interfere with the
interpretation of study results and, in the judgment of the investigator, would make
the patient inappropriate for entry into this study.
- - Known prior severe hypersensitivity to investigational product or any component in its
formulations that could interfere with study endpoints or put patient safety at risk.
- Pregnant or breast-feeding women